Positive status of Hepatis B Virus seroprevalence in local people and immigrants

Year 2023, Volume: 5 Issue: 1, 26 - 32, 29.01.2023

Salih Metin , Canan Demir

https://doi.org/10.46310/tjim.1215109

Abstract

Background In our study, we aimed to examine the seroprevalence of hepatitis B virus (HBV) infection and whether there is a sociodemographic difference between the two groups according to the hepatitis B surface antigen (HBsAg) results obtained in the blood samples given by the Turkish population and Syrian immigrants living in Bursa in their primary, secondary, and tertiary care applications.
Material and Methods All patients with HBsAg serology who applied to family health centers, migrant health centers, 2nd and 3rd level hospitals in Bursa province during the 5-year period from January 2017 to the end of December 2021 were included in our study.
Results During our study, HBsAg tests were taken from 955,528 people until the end of 2017-2021. The rate of Turkish citizens was 96.1% (n: 918,140), and the rate of Syrian origin was 3.9% (n: 37,388). Of all patients, 39.4% (n: 376,388) were male, and 60.6% (n: 579,140) were female. The HBsAg test was negative in 96.4% (n: 921,582) and positive in 3.6% (n: 33,946) of the patients. HBsAg positivity was found to be 3.6% in Turks and 2.4% in Syrians. HBsAg positivity was found to be 4.6% in men and 2.9% in women. The highest HBsAg positivity rate was 7.4% in the 50-59 age group.
Conclusions The dissemination of the hepatitis B vaccine, which is currently in use, seems to be the most crucial weapon in the hands of humanity to prevent this infection and the diseases it will cause.

Keywords

seroprevalans, immigrants, hbv

References

• World Health Organization (WHO). Hepatitis B June 24, 2022. Available at: https://www.who.int/newsroom/fact-sheets/detail/hepatitis-b. Accessed November 01, 2022.
• World Health Statistics 2016: Monitoring health for the SDGs sustainable development goals. World Health Organization. Geneva, Switzerland: WHO Press; 2016.
• Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, Coppola N. Hepatitis B virus burden in developing countries. World J Gastroenterol. 2015 Nov 14;21(42):11941-53. doi: 10.3748/wjg.v21.i42.11941.
• Nworie O, Jerry OO, Ekuma UO, Ukpabi NN, Onu EN. Studies on the seroprevalence of hepatitis B virus infection among school children in Ohaukwu, Ebonyi state, Nigeria. World Appl Sci J. 2015;33(11):1767-72. doi: 10.5829/idosi.wasj.2015.33.11.15626.
• Göç İdaresi Başkanlığı. Geçici Koruma 2022. Available at: https://www.goc.gov.tr/gecici-koruma5638. Accessed November 04, 2022.
• Kao JH. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol. 2008 Aug;2(4):553-62. doi: 10.1586/17474124.2.4.553.
• Ringelhan M, McKeating JA, Protzer U. Correction to 'Viral hepatitis and liver cancer'. Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):20170339. doi: 10.1098/rstb.2017.0339.
• Mıstık R. Examination of viral hepatitis epidemiology publications in Turkey. Viral Hepatitis. 2007;1:10-50 (in Turkish).
• Gencer SK. Comparison of hepatitis B and hepatitis C seropositivity of the Syrian immigrant and Turkish local people. Viral Hepat J. 2022 Apr;28(1):32-7. doi: 10.4274/vhd.galenos.2022.2020-12-5.
• Toy M, Önder FO, Wörmann T, Bozdayi AM, Schalm SW, Borsboom GJ, van Rosmalen J, Richardus JH, Yurdaydin C. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: a systematic review. BMC Infect Dis. 2011 Dec 12;11:337. doi: 10.1186/1471-2334-11-337.
• Inci A, Guven D, Okay M. HBsAg, anti-HBs, anti-HCV and anti-HIV seroprevalence of the patients applied to Artvin state hospital. Viral Hepat J. 2013 Apr;19(1):41-4 (in Turkish). doi: 10.4274/Vhd.03522.
• Asan A, Akbulut A, Saçar S, Turgut H. Evaluation of seroprevalence of HBsAg and Anti-HCV in the patients admitted to the Tunceli state hospital. Viral Hepat J. 2011 Mar;17(2):52-6 (in Turkish).
• Demirpençe Ö, Tezcan SI, Değirmen E, Mert D, Gümüş A, Çelen MK. Results of hepatitis and HIV serology in people admitted to Batman State Hospital. Viral Hepat J. 2012 Apr;18(1):6-10 (in Turkish). doi: 10.4274/Vhd.18.02.
• Dursun M, Gul K, Yilmaz Ş, Canoruç F, Ayyildiz O, Değertekin H. HBsAg and anti-HCV positivity ratios of volunteer blood donors admitted to blood centers in Diyarbakır. The Turkish Journal of Academic Gastroenterology. 2003 Dec;2(3):130-3 (in Turkish).
• Kurt H, Battal İ, Memikoğlu O, Yeşilkaya A, Tekeli E. The spectrum of seropositivity of HAV, HBV, HCV according to age and sex in healty population in Ankara. Viral Hepat J. 2003;8(2):88-96 (in Turkish).
• Tekay F. Seroprevalence of HBV, HCV and HIV in Hakkari Province. Dicle Tıp Dergisi. 2006;33(3):170-3 (in Turkish).
• Tunç N, Eraydın H, Çetinkaya E, Oduncu MK, Toy Ş. HBsAg, anti-HBs, anti-HCV and anti-HIV seroprevalence of the patients apply to Siirt public hospital. Viral Hepat J. 2011;17(1):7-11 (in Turkish).
• Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, McGlynn KA. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013 Aug;108(8):1314-21. doi: 10.1038/ajg.2013.160.
• Wu EM, Wong LL, Hernandez BY, Ji JF, Jia W, Kwee SA, Kalathil S. Gender differences in hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. Hepatoma Res. 2018;4:66. doi: 10.20517/2394-5079.2018.87.
• Yacoub R, Al Ali R, Moukeh G, Lahdo A, Mouhammad Y, Nasser M. Hepatitis B vaccination status and needlestick injuries among healthcare workers in syria. J Glob Infect Dis. 2010 Jan;2(1):28-34. doi: 10.4103/0974-777X.59247.
• Nguyen MH, Lim JK, Burak Ozbay A, Fraysse J, Liou I, Meyer N, Dusheiko G, Gordon SC. Advancing age and comorbidity in a US insured population-based cohort of patients with chronic hepatitis B. Hepatology. 2019 Mar;69(3):959-73. doi: 10.1002/hep.30246.
• Lai JC, Wong VW, Yip TC, Hui VW, Tse YK, Lee HW, Liang LY, Lui GC, Chan HL, Wong GL. Secular trend of treatment uptake in patients with chronic hepatitis B: A territory-wide study of 135 395 patients from 2000 to 2017. J Gastroenterol Hepatol. 2021 Dec;36(12):3487-99. doi: 10.1111/jgh.15664.
• Gnyawali B, Pusateri A, Nickerson A, Jalil S, Mumtaz K. Epidemiologic and socioeconomic factors impacting hepatitis B virus and related hepatocellular carcinoma. World J Gastroenterol. 2022 Aug 7;28(29):3793-802. doi: 10.3748/wjg.v28.i29.3793.